Compare PLSM & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSM | PLUR |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7M | 18.5M |
| IPO Year | 2025 | 2001 |
| Metric | PLSM | PLUR |
|---|---|---|
| Price | $2.22 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 44.8K | 24.5K |
| Earning Date | 03-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,016,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.26 | $1.06 |
| 52 Week High | $12.97 | $4.87 |
| Indicator | PLSM | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 31.47 | 32.26 |
| Support Level | N/A | N/A |
| Resistance Level | $2.88 | $1.85 |
| Average True Range (ATR) | 0.24 | 0.12 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 19.35 | 10.80 |
Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.